Agios Pharmaceuticals | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.86B 306M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Arrowhead Research USD 30.2M 1.91M 2024-12
Astellas Pharma JPY 225.3B 25.77B 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Bayer EUR 4.34B 610M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Daiichi Sankyo JPY 185.63B 23.39B 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
Incyte USD 326.71M 17.5M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
Merck USD 2.85B 148M 2024-12
Moderna USD 351M 70M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Agios Pharmaceuticals Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.